U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07107256) titled 'Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps' on July 23.
Brief Summary: TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Intervention:
DRUG: TQ...